Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
- PMID: 17024116
- DOI: 10.1038/sj.leu.2404413
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
Abstract
Fluorescence in situ hybridization (FISH) has become a powerful technique for prognostic assessment in multiple myeloma (MM). However, the existence of associations between cytogenetic abnormalities compels us to re-assess the value of each abnormality. A total of 260 patients with MM at the time of diagnosis, enrolled in the GEM-2000 Spanish transplant protocol, have been analyzed by FISH in order to ascertain the independent influence on myeloma prognosis of IGH translocations, as well as RB and P53 deletions. Survival analyses showed that patients with t(4;14), RB or P53 deletions had a significantly shorter survival than patients without these abnormalities. However, patients with RB deletions without other abnormalities in FISH analysis, displayed a similar outcome to those patients without genetic changes by FISH (46 vs 54 months, P=0.3). In the multivariate analysis the presence of t(4;14), RB deletion associated with other abnormalities, age >60 years, high proportion of S-phase cells and advanced stage of the disease according to the International Staging System retained their independent prognostic influence. In summary, RB deletion as a sole abnormality does not lead to a shortening in the survival of MM patients, whereas t(4;14) confers the worst prognosis in MM patients treated with high-dose chemotherapy.
Similar articles
-
The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):227-35. doi: 10.1016/j.clml.2014.12.007. Epub 2014 Dec 12. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25812994
-
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.Haematologica. 2010 Jul;95(7):1150-7. doi: 10.3324/haematol.2009.016436. Epub 2010 Mar 10. Haematologica. 2010. PMID: 20220069 Free PMC article.
-
Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.Br J Haematol. 2007 Oct;139(1):51-4. doi: 10.1111/j.1365-2141.2007.06750.x. Br J Haematol. 2007. PMID: 17854306
-
[Genetic markers as prognostic factors in multiple myeloma].Rev Med Chil. 2009 Apr;137(4):552-8. Epub 2009 Jun 25. Rev Med Chil. 2009. PMID: 19623423 Review. Spanish.
-
[Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].Rev Med Interne. 2007 Oct;28(10):677-81. doi: 10.1016/j.revmed.2007.04.013. Epub 2007 May 25. Rev Med Interne. 2007. PMID: 17559979 Review. French.
Cited by
-
Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities.Oncol Rev. 2012 Oct 4;6(2):e14. doi: 10.4081/oncol.2012.e14. eCollection 2012 Oct 2. Oncol Rev. 2012. PMID: 25992212 Free PMC article. Review.
-
Small compound bigelovin exerts inhibitory effects and triggers proteolysis of E2F1 in multiple myeloma cells.Cancer Sci. 2013 Dec;104(12):1697-704. doi: 10.1111/cas.12295. Epub 2013 Nov 8. Cancer Sci. 2013. PMID: 24118350 Free PMC article.
-
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential.Leukemia. 2015 May;29(5):1186-94. doi: 10.1038/leu.2014.321. Epub 2014 Nov 12. Leukemia. 2015. PMID: 25388955
-
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.Leukemia. 2012 Feb;26(2):349-55. doi: 10.1038/leu.2011.204. Epub 2011 Aug 12. Leukemia. 2012. PMID: 21836613 Free PMC article.
-
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.Haematologica. 2010 Nov;95(11):1913-20. doi: 10.3324/haematol.2010.028027. Epub 2010 Jul 27. Haematologica. 2010. PMID: 20663944 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous